ImmunoCellular Therapeutics Ltd  

(Public, NYSEMKT:IMUC)   Watch this stock  
Find more results for imuc
0.890
-0.020 (-2.20%)
Sep 30 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.88 - 0.91
52 week 0.65 - 4.00
Open 0.90
Vol / Avg. 326,823.00/332,556.00
Mkt cap 55.21M
P/E     -
Div/yield     -
EPS -0.16
Shares 60.67M
Beta 1.18
Inst. own 10%
Nov 3, 2014
Q3 2014 ImmunoCellular Therapeutics Ltd Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 7, 2014
Q2 2014 ImmunoCellular Therapeutics Ltd Earnings Call
Aug 7, 2014
Q2 2014 IMMUNOCELLULAR THERAPEUTICS Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -33.02% -31.45%
Return on average equity -36.56% -35.53%
Employees 3 -
CDP Score - -

Address

Suite 300, 23622 Calabasas Road
CALABASAS, CA 91302
United States - Map
+1-818-2642300 (Phone)
+1-818-2245287 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient�s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company�s products include ICT-107, ICT-140, ICT-121, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient�s immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).

Officers and directors

John S. Yu M.D. Chairman of the Board, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Andrew Gengos President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Anthony J. Gringeri Ph.D. Senior Vice President - Strategic Resources
Age: 60
Bio & Compensation  - Reuters
David E. Fractor Principal Accounting Officer, Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
Rahul Singhvi Lead Independent Director
Age: 49
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Gary S. Titus Independent Director
Age: 54
Bio & Compensation  - Reuters